Stamaril

Stamaril

vaccine, yellow fever

Manufacturer:

Sanofi Pasteur
Concise Prescribing Info
Contents
Attenuated yellow fever virus (17D/AB 237 strain)
Indications/Uses
Prevention of yellow fever for travelers to endemic areas.
Dosage/Direction for Use
Adult & childn ≥9 mth 0.5 mL as single SC/IM dose valid for 10 yr after 10 days of initial vaccination or revaccination.
Contraindications
True allergy to one of the vaccine components, & notably egg albumin, congenital or acquired immunodeficiency except HIV, active malignancy, serious disease. Combination w/ cytotoxic agents. Infant <9 mth.
Special Precautions
Do not administer by intravascular route. Avoid vaccination against yellow fever in case of HIV‐positive patients who are symptomatic, in whom CD4 levels are <200/mm3 or those w/ a high viral load. Vaccination may be undertaken in other HIV-positive patients. Delay vaccination for 1 mth in patients who received immunosuppressant therapy. Tolerability test in allergic subjects. Delay vaccination in the event of fever, acute disease or active chronic disease.
Adverse Reactions
Fever, fatigue, headache, neurological disorders eg, meningitis, enchepalitis & meningoencephalitis, multivisceral deficiency, anaphylactic reactions.
Drug Interactions
Risk of systemic vaccinal disease w/ cytotoxic agents, other immunosuppressants: cyclosporin, tacrolimus, globulins, antilymphocyte agents, glucocorticosteroids, except for hydrocortisone employed as replacement therapy in Addison's disease (systemic & topical routes: intraarticular, cutaneous & enema), tetracosactide.
ATC Classification
J07BL01 - yellow fever, live attenuated ; Belongs to the class of yellow fever viral vaccines.
Presentation/Packing
Form
Stamaril vaccine (inj) ≥1000 U/dose
Packing/Price
(vial + 0.5 mL pre-filled syringe (diluent)) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in